Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. on February 12, 2018. The filing reports a material event regarding a proposed underwritten public offering of the Company's common stock. Note: The request metadata references "Gyre Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Catalyst Biosciences, Inc.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the announcement of a capital raise rather than reporting periodic financial results.
Material Changes
The primary material change is the initiation of an underwritten public offering of common stock, subject to market conditions. The Company intends to sell all shares in this offering.
Guidance, Outlook, and Management Commentary
- Use of Proceeds: Net proceeds are intended for general corporate purposes, including clinical and manufacturing activities for CB 2679d and Marzeptacog alfa (activated), research and development, capital expenditures, selling, general and administrative costs, and working capital needs.
- Underwriters: JonesTrading Institutional Services LLC is the Sole Bookrunning Manager. Ladenburg Thalmann & Co. Inc. is the Joint Bookrunner, and LifeSci Capital LLC is a Lead Manager.
- Conditions: The offering is subject to market conditions.
Investor Verification Checklist
- Verify the final terms of the offering (share count and price) once the prospectus is filed, as this 8-K only announces the intent.
- Confirm the specific allocation of proceeds between the two named drug candidates (CB 2679d and Marzeptacog alfa).
- Review the attached press release (Exhibit 99.1) for additional details on the offering structure.
- Check subsequent filings for the completion status of the offering.